2-Piperidone → 1-({4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}methyl)-2-piperidinone
반응식
Cl[CH2:2][C:3]1[CH:8]=[CH:7][C:6]([N:9]2[C:17]3[CH2:16][CH2:15][CH2:14][CH2:13][C:12]=3[C:11]([C:18]([F:21])([F:20])[F:19])=[N:10]2)=[CH:5][CH:4]=1.[NH:22]1[CH2:27][CH2:26][CH2:25][CH2:24][C:23]1=[O:28]>>[F:19][C:18]([F:21])([F:20])[C:11]1[C:12]2[CH2:13][CH2:14][CH2:15][CH2:16][C:17]=2[N:9]([C:6]2[CH:7]=[CH:8][C:3]([CH2:2][N:22]3[CH2:27][CH2:26][CH2:25][CH2:24][C:23]3=[O:28])=[CH:4][CH:5]=2)[N:10]=1참가 물질
3
실험 절차
The title compound was prepared from 1-[4-(chloromethyl)phenyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole and 2-piperidinone using a similar procedure to that described for Description 15.
출처 및 근거
- ORD 기록
- ord-5ebce77d11dd4a6ca94db455fa584f89
- 출처 데이터셋
- uspto-grants-2009_07
- 특허 번호
- US07566735B2
반응 노트
불러오는 중…